Literature DB >> 29999428

Misconceptions and issues regarding allometric scaling during the drug development process.

Iftekhar Mahmood1.   

Abstract

INTRODUCTION: Allometry is the study of size and its consequences. The simple hypothesis of allometric scaling is that all physiological parameters are proportional to body size or body mass. This review examines the development of theory-based allometry or fixed exponents (0.75 and 1.0 for basal metabolic rate and volume, respectively) and the evidence for or against the theory. The main focus of this report is to show the readers that there is enough evidence from experimental data that negate the concept of theory-based allometry in biology, physiology, and pharmacokinetics. Areas covered: In this review, the history of the development of theoretical allometry and the strong evidence against theory-based allometry demonstrated by experimental data is provided. During drug development, allometry is applied to both inter-species (from animals to humans) and intra-species (adults to children) scaling. These two forms of allometric scaling in the context of theory-based allometry are discussed and provide insight on scientific progress that refute theory-based allometry. Expert opinion: Theory-based allometry is a mere theory and experimental data and real-life observations strongly negate the existence of such a theory. Pharmacostatistical and physiological models based on theory-based allometry can be misleading and incorrect because the theory-based allometric exponent 0.75 is not universal. The exponents of allometry are data dependent and are not fixed in the universe.

Entities:  

Keywords:  Allometric models; basal metabolic rate; drug clearance; inter-species scaling; pediatrics; pharmacokinetics; theory-based allometry

Mesh:

Substances:

Year:  2018        PMID: 29999428     DOI: 10.1080/17425255.2018.1499725

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  5 in total

1.  A Simple Method for the Prediction of Human Concentration-Time Profiles and Pharmacokinetics of Antibody-Drug Conjugates (ADC) from Rats or Monkeys.

Authors:  Iftekhar Mahmood
Journal:  Antibodies (Basel)       Date:  2022-06-14

2.  Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney disease.

Authors:  Mandy Wan; Bruce Green; Arpana Aprameya Iyengar; Nivedita Kamath; Hamsa V Reddy; Jyoti Sharma; Jyoti Singhal; Susan Uthup; Sudha Ekambaram; Sumithra Selvam; Greta Rait; Rukshana Shroff; Jignesh P Patel
Journal:  Br J Clin Pharmacol       Date:  2021-09-30       Impact factor: 3.716

3.  A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children.

Authors:  Janneke M Brussee; Elke H J Krekels; Elisa A M Calvier; Semra Palić; Amin Rostami-Hodjegan; Meindert Danhof; Jeffrey S Barrett; Saskia N de Wildt; Catherijne A J Knibbe
Journal:  AAPS J       Date:  2019-06-27       Impact factor: 4.009

4.  Predictive performance of pharmacokinetic models for target concentration-controlled infusion of cefoxitin as a prophylactic antibiotic in patients with colorectal surgery.

Authors:  Byung-Moon Choi; Seok Hwan Lee; Hyun-Uk Kang; Kyung Mi Kim; Jae Moon Choi; Eun-Kyung Lee; Gyu-Jeong Noh
Journal:  Clin Exp Pharmacol Physiol       Date:  2022-07-13       Impact factor: 2.963

Review 5.  Clinical Pharmacology of Antibody-Drug Conjugates.

Authors:  Iftekhar Mahmood
Journal:  Antibodies (Basel)       Date:  2021-05-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.